Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field.

Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer.

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer.

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.

Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer.

Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer.

Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer.

Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting.

Featuring a roundtable discussion on the current and future role of PARP inhibitor-based therapy in the management of prostate cancer, with Drs Neeraj Agarwal, Emmanuel Antonarakis, Susan Slovin, and Prof Karim Fizazi, moderated by Dr Neil Love.

Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Professor Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer, moderated by Dr Neil Love.

Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York, discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer, moderated by Dr Neil Love.